164 related articles for article (PubMed ID: 30423481)
21. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
[TBL] [Abstract][Full Text] [Related]
22. Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation.
Shultes KC; Arp C; Stockerl-Goldstein K; Trinkaus K; DeFrates S
Biol Blood Marrow Transplant; 2018 Apr; 24(4):687-693. PubMed ID: 29225163
[TBL] [Abstract][Full Text] [Related]
23. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
Sugimoto M; Ito S; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Ashizawa M; Yamamoto C; Fujiwara S; Okazuka K; Hatano K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kako S; Kanda Y
Ann Hematol; 2016 Sep; 95(9):1513-9. PubMed ID: 27365141
[TBL] [Abstract][Full Text] [Related]
24. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
[TBL] [Abstract][Full Text] [Related]
25. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Sivaraj D; Bacon W; Long GD; Rizzieri DA; Horwitz ME; Sullivan KM; Kang Y; Li Z; Chao NJ; Gasparetto C
Bone Marrow Transplant; 2018 Jan; 53(1):34-38. PubMed ID: 29084203
[TBL] [Abstract][Full Text] [Related]
26. High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
Noesslinger T; Panny M; Simanek R; Moestl M; Boehm A; Menschel E; Koller E; Keil F
Eur J Haematol; 2018 Sep; 101(3):326-331. PubMed ID: 29799642
[TBL] [Abstract][Full Text] [Related]
27. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
28. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
29. Body mass index does not impact hematopoietic progenitor cell mobilization for autologous hematopoietic cell transplantation.
Khouri J; Rybicki L; Majhail NS; Kalaycio M; Pohlman B; Hill B; Jagadeesh D; Dean R; Hamilton B; Sobecks R; Koo A; Liu H
J Clin Apher; 2019 Dec; 34(6):638-645. PubMed ID: 31381194
[TBL] [Abstract][Full Text] [Related]
30. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
31. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
32. A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.
Kothari J; Foley M; Peggs KS; Mackenzie S; Thomson K; Morris E; Ardeshna KM; Virchis AE; Linch DC; Lambert J
Bone Marrow Transplant; 2016 Oct; 51(10):1397-1399. PubMed ID: 27214072
[No Abstract] [Full Text] [Related]
33. Autologous Hematopoietic Stem Cell Transplantation-10 Years of Data From a Developing Country.
Ali N; Adil SN; Shaikh MU
Stem Cells Transl Med; 2015 Aug; 4(8):873-7. PubMed ID: 26032748
[TBL] [Abstract][Full Text] [Related]
34. Y
Voegeli M; Rondeau S; Berardi Vilei S; Lerch E; Wannesson L; Pabst T; Rentschler J; Bargetzi M; Jost L; Ketterer N; Bischof Delaloye A; Ghielmini M
Hematol Oncol; 2017 Dec; 35(4):576-583. PubMed ID: 27677906
[TBL] [Abstract][Full Text] [Related]
35. Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma.
Dahi PB; Lazarus HM; Sauter CS; Giralt SA
Bone Marrow Transplant; 2019 Jul; 54(7):943-960. PubMed ID: 30390059
[TBL] [Abstract][Full Text] [Related]
36. LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.
Khattry N; Gupta A; Jain R; Gore A; Thippeswamy R; Jeevangi N; Kannan S; Nair R; Saikia T
Int J Hematol; 2016 Mar; 103(3):292-8. PubMed ID: 26729297
[TBL] [Abstract][Full Text] [Related]
37. Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity.
Shi Y; Liu P; Zhou S; Yang J; Han X; He X; Zhang C; Gui L; Qin Y; Yang S; Zhao L; Yao J; Jia B; Zhang S; Sun Y; Shi Y
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e423-e429. PubMed ID: 28101911
[TBL] [Abstract][Full Text] [Related]
38. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Shimoni A; Avivi I; Rowe JM; Yeshurun M; Levi I; Or R; Patachenko P; Avigdor A; Zwas T; Nagler A
Cancer; 2012 Oct; 118(19):4706-14. PubMed ID: 22252613
[TBL] [Abstract][Full Text] [Related]
39. Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation.
Huang H; Zhang L; Jiang Y; Liu S; Jin Z; Chen J; Xiao X; Ruan J; Zhang X; Wu D
Ann Hematol; 2019 May; 98(5):1259-1266. PubMed ID: 30635767
[TBL] [Abstract][Full Text] [Related]
40. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
Isidori A; Christofides A; Visani G
Leuk Lymphoma; 2016 Nov; 57(11):2499-509. PubMed ID: 27243412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
